BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.
BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.